prop-2-ynyl (5R)-1,4,5,6-tetrahydropyrimidine-5-carboxylate | 185444-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: prop-2-ynyl (5R)-1,4,5,6-tetrahydropyrimidine-5-carboxylate
• CAS: 185444-95-5
• 化学式: C₈H₁₀N₂O₂
• 分子量: 166.18
• InChiKey: KEBHGVXTLDRPHQ-UHFFFAOYSA-N

物化性质

• 沸点：
  392.3±32.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• MUSCARINIC AGONISTS
  申请人：THE UNIVERSITY OF TOLEDO

  公开号：EP0630244A1

  公开（公告）日：1994-12-28
• METHOD FOR TREATING UNDERACTIVE BLADDER SYNDROME
  申请人：William Beaumont Hospital

  公开号：US20170333407A1

  公开（公告）日：2017-11-23

  Disclosed are nonlimiting embodiments comprising novel methods for treating underactive bladder in a subject, including administering an effective amount of a pharmaceutical composition comprising an M1-selective muscarinic agonist to the subject. In some embodiments, the M1-selective muscarinic agonist is cevimeline.
• [EN] MUSCARINIC AGONISTS
  申请人：——

  公开号：WO1993003726A1

  公开（公告）日：1993-03-04

  [FR] On décrit des compositions de 1,4,5,6-tétrahydropyrimidine substituées, des compositions de 1,2,3,6-tétrahydropyrimidine substituées ainsi que des compositions de 3,4,5,6-tétrahydropyrimidine substituées. Lesdites compositions sont destinées à être utilisées pour la stimulation des récepteurs muscariniques comprenant, par exemple, le traitement des symptômes des troubles cognitifs, notamment la mémoire défaillante, qui sont associées à la synthèse diminuée de l'acétylcholine et à la génération de cellules cholinergiques.
  [EN] Substituted 1,4,5,6-tetrahydropyrimidine compositions, substituted 1,2,3,6-tetrahydropyrimidine compositions and substituted 3,4,5,6-tetrahydropyrimidine compositions are disclosed. They are useful for stimulating muscarinic receptors including, for example, treating the symptoms of cognitive disorders, especially impaired memory, which are associated with decreased acetylcholine synthesis and cholinergic cell degeneration.
• [EN] METHOD FOR TREATING UNDERACTIVE BLADDER SYNDROME<br/>[FR] PROCÉDÉ DE TRAITEMENT DU SYNDROME DE LA VESSIE HYPOACTIVE
  申请人：BEAUMONT HOSPITAL WILLIAM

  公开号：WO2016073294A1

  公开（公告）日：2016-05-12

  Disclosed are nonlimiting embodiments comprising novel methods for treating underactive bladder in a subject, including administering an effective amount of a pharmaceutical composition comprising an Ml -selective muscarinic agonist to the subject. In some embodiments, the Ml -selective muscarinic agonist is cevimeline.